Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg

Advances in Medical Sciences

Volumn 57, Issue 2, 2012, Pages 217-223

  Szalek, E ^a   Tomczak, H ^b   Kaminska A ^a   Grabowski, T ^c   Smuszkiewicz, P ^b   Matysiak, K ^a   Wolc, A ^d   Kaczmarek, Z ^a   Grzeoekowiak E ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b University Hospital   (Poland)

^c POLPHARMA BIOLOGICS   (Poland)

^d POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

AUIC; Ciprofloxacin; Cmax MIC; Critically ill patients; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; CREATININE;

ACINETOBACTER BAUMANNII; ACINETOBACTER LWOFFII; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD SAMPLING; CLINICAL ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTION; KIDNEY FAILURE; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS FLUORESCENS; STENOTROPHOMONAS MALTOPHILIA;

EID: 84879595116     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0028-4     Document Type: Article

References (41)

1. Smuszkiewicz P, Sza?ek E, Tomczak H, Trojanowska I, B?aszyk M. Farmakokinetyczno-farmakodynamiczne zasady stosowania antybiotyków u chorych leczonych z powodu sepsy [Pharmacokinetic and pharmacodynamic considerations of antimicrobial therapy in sepsis]. Anest Intens Ter. 2007 39(3):166-174. Polish.
2. Scaglione F, Paraboni L. Pharmacokinetics/ pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents. 2008 Oct;32(4):294-301.
3. Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother. 1998 Sep;42(9):2235-9. (Pubitemid 28420356)
4. Gous A, Lipman J, Scribante J, Tshukutsoane S, Hon H, Pinder M, Mathivha R, Verhoef L, Stass H. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents. 2005 Jul;26(1):50-5. (Pubitemid 40854116)
5. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996 Jun;51(6):1019-74.
6. Drzewiecki A. Dlaczego lewofloksacyna zosta?a g?ównym .,szpitalnym" fluorochinolonem w krajach zachodnich? [Why has levofloxacin become main "hospital" fluoroquinolon is Western countries?]. Zaka¿enia. 2010 6:39-45. Polish.
7. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62(1):13-59. (Pubitemid 34169425)
8. Wiseman LR, Balfour JA. Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging. 1994 Feb;4(2):145-73.
9. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008 Sep;23(3):422-30.
10. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standarization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005 May;55(5):601-7.
11. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents. 2002 Apr;19(4):349-53. (Pubitemid 34326395)
12. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther. 2006 Jun;4(3):479-90. (Pubitemid 43905469)
13. Woodnutt G. Pharmacodynamics to combat resistance. J Antimicrob Chemother. 2000 Jul;46 Suppl T1:25 31. (Pubitemid 30468445)
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
15. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care. 2011 Jun 8;15(3):R139.
16. Maya MT, Goncalves NJ, Silva NB, Morais JA. Simple high-performance liquid chromatographic assay for the determination of ciprofloxacin in human plasma with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001 May 5;755(1-2):305-9. (Pubitemid 32324097)
17. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/ pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004 Feb;48(2):125-30. (Pubitemid 38221508)
18. Wise R. Maximizing efficacy and reducing the emergence of resistance. J Antimicrob Chemother. 2003 May;51 Suppl 1:37-42. (Pubitemid 36622103)
19. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009 Mar;37(3):840-51.
20. Ghazal HH, Ghazal CD, Tabbara IA. Ceftazidime and ciprofloxacin as empiric therapy in febrile neutropenic patients undergoing hematopoietic stem cell transplantation. Clin Ther. 1997 May- Jun;19(3):520-6. (Pubitemid 27292592)
21. Griggs JJ, Blair EA, Norton JR, Rowe JM, Flesher WR, Betts RF. Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy. Am J Hematol. 1998 Aug;58(4):293-7. (Pubitemid 28346015)
22. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, Glauser M. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May;35(5):873-8.
23. Neu HC. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs. 1993;45 Suppl 3:54-8.
24. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs. 2005;65(7):949-91. (Pubitemid 40663622)
25. Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother. 1999 Dec;11(6):426-39. (Pubitemid 30029540)
26. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents. 2009 Jul;34(1):82-5.
27. Brown AE, Smith G. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. Am J Med. 1989 Nov 30;87(5A):266S-268S. (Pubitemid 20005200)
28. Duszyńska W. Antimicrobial therapy in severe infections with multidrug-resistant Gram-negative bacteria. Anest Intens Ter. 2010 Jul-Sep;42(3):160-6.
29. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993 May;37(5):1065-72. (Pubitemid 23141322)
30. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. (Pubitemid 33107864)
31. Odoul F, Le Guellec C, Giraut C, de Gialluly C, Marchand S, Paintaud G, Saux MC, Rolland JC, Autret- Leca E. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses. Therapie. 2001 Sep-Oct;56(5):519-24. (Pubitemid 34027024)
32. Sánchez Navarro MD, Sayalero Marinero ML, Sánchez Navarro A. Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. J Antimicrob Chemother. 2002 Jul;50(1):67-72. (Pubitemid 34785256)
33. Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):440-3. (Pubitemid 16017325)
34. Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, Forrest A, Drusano GL. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985 Aug;28(2):235-9. (Pubitemid 15019955)
35. Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet. 2003;42(6):589-98. (Pubitemid 36801876)
36. Höffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol. 1984 Aug;3(4):363-6. (Pubitemid 14034603)
37. Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol. 1996 Nov;42(5):632-4. (Pubitemid 26385269)
38. Konieczna L, Chmielewska A, Lamparczyk H. Influence of sex on the pharmacokinetics of ciprofloxacin and ofloxacin. Chemotherapy. 2006;52(3):111-21. (Pubitemid 43760307)
39. Overholser BR, Kays MB, Forrest A, Sowinski KM. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol. 2004 Sep;44(9):1012-22. (Pubitemid 39096816)
40. Conil JM, Georges B, de Lussy A, Khachman D, Seguin T, Ruiz S, Cougot P, Fourcade O, Houin G, Saivin S. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents. 2008 Dec;32(6):505-10.
41. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073-81.